참고문헌
- Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of an ti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-2454. https://doi.org/10.1056/NEJMoa1200690
- Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139-148. https://doi.org/10.1016/j.ejca.2015.11.016
- Bot I, Blank CU, Boogerd W, Brandsma D. Neurological immune-related adverse events of ipilimumab. Pract Neurol 2013;13:278-280. https://doi.org/10.1136/practneurol-2012-000447
- Motamed-Gorji N, Matin N, Tabatabaie O, Pavone P, Romano C, Falsaperla R, et al. Biological drugs in Guillain-Barre syndrome: an update. Curr Neuropharmacol 2017;15:938-950.
- Sakai K, Mochizuki H, Mochida K, Shiomi K, Amano M, Nakazato M. A case of nivolumab-induced severe mononeuropathy multiplex and rhabdomyolysis. Case Rep Med 2017;2017:1093858.
- Gu Y, Menzies AM, Long GV, Fernando SL, Herkes G. Immune mediated neuropathy following checkpoint immunotherapy. J Clin Neurosci 2017;45:14-17. https://doi.org/10.1016/j.jocn.2017.07.014
- Fukumoto Y, Kuwahara M, Kawai S, Nakahama K, Kusunoki S. Acute demyelinating polyneuropathy induced by nivolumab. J Neurol Neurosurg Psychiatry 2018;89:435-437. https://doi.org/10.1136/jnnp-2017-316510
- Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30:2691-2697. https://doi.org/10.1200/JCO.2012.41.6750
- Williams TJ, Benavides DR, Patrice KA, Dalmau JO, de Avila AL, Le DT, et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016;73:928-933. https://doi.org/10.1001/jamaneurol.2016.1399
- Ito M, Fujiwara S, Fujimoto D, Mori R, Yoshimura H, Hata A, et al. Rituximab for nivolumab plus ipilimumab - induced encephalitis in a small-cell lung cancer patient. Ann Oncol 2017;28:2318-2319. https://doi.org/10.1093/annonc/mdx252